Leadership Change at BerGenBio ASA
BerGenBio ASA, a prominent biopharmaceutical company, has made significant strides in the healthcare sector with the recent appointment of Olav Hellebø as its new Chief Executive Officer. This strategic leadership shift sets the stage for innovation and progress within the company as it continues its mission to address critical unmet medical needs.
Meet Olav Hellebø
Olav Hellebø is not a stranger to the dynamic world of biopharmaceuticals. With over three decades of extensive experience in the pharmaceutical and biotechnology industries, Hellebø brings a wealth of knowledge and a proven track record to BerGenBio. His previous roles have provided him the expertise needed to navigate the complexities of the clinical landscape, particularly in immuno-oncology.
Background and Experience
Hellebø's career highlights include significant positions within reputable organizations. Most recently, he served as a board director at Cytovation ASA, where he influenced clinical-stage initiatives in immuno-oncology. His leadership at Antev Ltd also shaped advancements in urology and oncology treatments. Before that, he held key leadership roles as CEO at both ReNeuron Group PLC and Clavis Pharma ASA.
Vision for the Future
As he steps into his new role, Hellebø expresses enthusiasm about the challenges and opportunities ahead. He emphasized the importance of BerGenBio's research into highly selective AXL inhibitors, particularly for patients battling non-squamous non-small cell lung cancer (NSCLC) with STK11 gene mutations. The primary aim of developing the candidate drug, bemcentinib, has the potential to transform treatment protocols for these patients.
Commitment to Clinical Development
In his remarks, Hellebø highlighted his eagerness to collaborate closely with the Board of Directors and the talented team at BerGenBio. Together, they will make critical advancements through the ongoing Ph1b/2a BGBC016 clinical trial. His unique perspective gained through previous successes positions him to effectively guide the company's innovative strategies.
Strengthening BerGenBio's Strategy
The Chairman of the Board, Anders Tullgren, commended Hellebø's exceptional qualifications. Tullgren stated that Hellebø's extensive experience in raising capital and securing strategic partnerships positions BerGenBio to optimize its investment as it transitions into this new phase of growth.
About BerGenBio ASA
BerGenBio ASA is driven by a mission to develop novel AXL inhibitors to serve as a cornerstone therapy for severe diseases, including various cancers and respiratory ailments. With a focus on bemcentinib, the company aims to establish a new standard of care for patients experiencing STK11 mutated NSCLC. BerGenBio operates from its headquarters in Bergen, Norway, with an additional office in Oxford, UK, and is publicly traded on the Oslo Stock Exchange under the ticker BGBIO, along with additional associated tickers like BRRGD and BRRGF.
Frequently Asked Questions
What is the significance of appointing Olav Hellebø as CEO?
Olav Hellebø's appointment is significant as he brings extensive pharmaceutical industry experience, crucial for guiding BerGenBio's innovative strategies.
What is BerGenBio's focus in drug development?
BerGenBio focuses on developing selective AXL inhibitors to treat aggressive diseases, including non-small cell lung cancer.
How does bemcentinib contribute to cancer treatment?
Bemcentinib is a potential first-in-class drug being developed to treat patients with STK11 gene mutations, aiming to improve treatment outcomes.
What are the company's future clinical trials?
The company is ongoing with its Ph1b/2a BGBC016 trial, crucial for the further development of bemcentinib.
Where is BerGenBio located?
BerGenBio is headquartered in Bergen, Norway, with a subsidiary presence in Oxford, UK.
